Dr Bertil Lindmark is Chief Medical Officer of ASLAN Pharmaceuticals. In his most recent position as Executive Director of Research and Development and Member of the Board of Directors at Almirall, a European pharmaceutical company with global reach, he led the global R&D team of more than 500 R&D staff across three sites, focusing on respiratory, gastrointestinal, dermatology and neuroscience. He secured EU and US approval of several important new drugs, including Eklira/Tudorza, Constella and Eklira/formoterol, and was instrumental in the USD$2bn sale of Almirall’s respiratory franchise to AstraZeneca. Prior to Almirall, Bertil was VP at AstraZeneca, leading global clinical development in Respiratory and Inflammation, notably securing the global approval of Symbicort Turbuhaler. He also served as VP and Head of Clinical Development at AstraZeneca Japan R&D leading 170 staff. During his career, Bertil has been responsible for the global approval of 10 drugs, with sales exceeding USD$4bn across three therapeutic areas, and has taken over 25 compounds into man. Bertil holds a MD degree and PhD in Molecular Epidemiology from the University of Lund, and specialist qualification in Internal Medicine and in Gastroenterology.

leading global clinical development in Respiratory and Inflammation